This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Avanos Medical (AVNS) Up 21% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Avanos (AVNS) Q3 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Avanos' (AVNS) third-quarter 2022 results reflect strength in the Pain Management segment.
Avanos Medical (AVNS) Tops Q3 Earnings Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 5.56% and 1.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
LivaNova (LIVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avanos Medical (AVNS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for October 5th
by Zacks Equity Research
AVNS, NKE and PLAB have been added to the Zacks Rank #5 (Strong Sell) List on October 5, 2022.
New Strong Sell Stocks for September 28th
by Zacks Equity Research
AVNS, ARCE and DCO have been added to the Zacks Rank #5 (Strong Sell) List on September 28, 2022.
Strength Seen in Treace Medical Concepts (TMCI): Can Its 8.4% Jump Turn into More Strength?
by Zacks Equity Research
Treace Medical Concepts (TMCI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Avanos Medical (AVNS) Down 14% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Avanos (AVNS) Q2 Earnings Top Estimates, FY22 View Lowered
by Zacks Equity Research
Avanos's (AVNS) second-quarter 2022 results reflect strength in the Pain Management segment.
Avanos Medical (AVNS) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 5.13% and 2.47%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Integer (ITGR) Q2 Earnings Miss Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of -11.86% and 1.41%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Inari Medical, Inc. (NARI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avanos Medical (AVNS) to Report Q2 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What to Expect From Molina Healthcare's (MOH) Q2 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) second-quarter results are likely to reflect benefits from higher premiums stemming from Medicaid and Medicare businesses, partly offset by elevated medical care costs.
Can Avanos Medical (AVNS) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Avanos Medical (AVNS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
Tandem Diabetes Care, Inc. (TNDM) Soars 6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Hold on to Avanos (AVNS) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
Avanos Medical (AVNS) Q1 Earnings, Revenues Top Estimates
by Zacks Equity Research
Avanos Medical's (AVNS) first-quarter 2022 results reflect strength in the Pain Management segment.
Avanos Medical (AVNS) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 8.33% and 0.97%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.
Abiomed (ABMD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q4 sales.